**Introduction to GIP (HUMAN)** GIP (HUMAN) is a cutting-edge biopharmaceutical product designed to harness the therapeutic potential of the human gastric inhibitory polypeptide (GIP). As a key metabolic hormone, GIP plays a vital role in glucose homeostasis, insulin secretion, and fat metabolism, making it a promising target for metabolic disorders like type 2 diabetes and obesity. Developed using advanced recombinant DNA technology, GIP (HUMAN) offers high purity and bioactivity, ensuring optimal efficacy in clinical applications. By modulating GIP receptor pathways, this innovative therapy aims to improve glycemic control, support weight management, and enhance overall metabolic health. Backed by rigorous research, GIP (HUMAN) represents a breakthrough in precision medicine for metabolic diseases.
Preparation Process: To prepare GIP (human), synthesize the 42-amino acid peptide (Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-Arg-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Ser-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln) using solid-phase peptide synthesis (SPPS) with Fmoc chemistry. Cleave the peptide from the resin using TFA, then purify via reverse-phase HPLC (C18 column, acetonitrile/water gradient). Lyophilize the purified product and confirm identity by mass spectrometry. For biological use, ensure endotoxin-free conditions and sterile filtration. Store at –20°C in lyophilized form or in PBS at 4°C for short-term use. Optimize folding if necessary.
Usage Scenarios: GIP (glucose-dependent insulinotropic polypeptide) is a hormone secreted by K cells in the small intestine in response to nutrient intake, particularly glucose and fat. Its primary role is to enhance insulin secretion from pancreatic β-cells in a glucose-dependent manner, aiding postprandial glucose regulation. GIP also promotes lipid storage in adipocytes by stimulating lipoprotein lipase activity. Additionally, it influences bone metabolism by inhibiting bone resorption. In research, GIP analogs and antagonists are studied for their potential in managing metabolic disorders like type 2 diabetes and obesity. GIP receptor agonists are being explored for their dual effects on glycemic control and weight regulation.